Drug reference

Vilanterol

LABA · Bronchodilator for COPD

LABABronchodilator for COPDATC R03AC12

CDSCO approvedSchedule HATC R03AC12

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

l MEDICINAL FORMS

FDA category + note

Top interactionssee all 12 →

MoclobemideSevereTextbookG&G 14e · p264
CarteololSevereDatabaseDDInter
CarvedilolSevereDatabaseDDInter
LabetalolSevereDatabaseDDInter

Mechanism

Vilanterol is an ultralong-acting beta2-adrenergic agonist. It selectively activates beta2 receptors in the bronchial smooth muscle, leading to relaxation and bronchodilation. This action provides sustained improvement in airflow for patients with chronic obstructive pulmonary disease.

Indications

Maintenance treatment of chronic obstructive pulmonary diseaseCOPD (in combination with fluticasone)COPD

Dosing

Adult: Umeclidinium bromide 65 microgram per 1 dose Incruse Ellipta 55micrograms/dose dry powder inhaler | 30 dose P £27.50 DT = £27.50 Combinations available: Fluticasone with umeclidinium and vilanterol, p. 279 Umeclidinium with vilanterol 16-Mar-2020 The properties listed below are those particular to the combination only. For the properties of the components please consider, umeclidinium above.…

Contraindications

Arrhythmias
Cardiovascular disease
Diabetes (risk of hyperglycaemia and ketoacidosis)
Hypertension
Hyperthyroidism
Hypokalaemia
Susceptibility to QT-interval prolongation

Side effects

Common

ConstipationDry mouthHeadacheOropharyngeal painSinusitisMuscle tremorTachycardiaPalpitations

Serious

Arrhythmias
Palpitations
Tremor
Bronchospasm paradoxical
Glaucoma
Urinary disorders
Vision blurred
Hypokalemia
Ventilation-perfusion (V/Q) mismatch (fall in arterial oxygen tension)
Metabolic effects (increase in free fatty acid, insulin, glucose, pyruvate, and lactate)
Life-threatening and fatal asthma exacerbations (if used alone in asthma)